Last reviewed · How we verify
NCT02605083
A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors
Terminated
Phase 1, PHASE2
Last updated 2 November 2020
What this trial tests
Phase 1, PHASE2 trial testing eFT508 in Cancer in 66 participants. Terminated before completion.
Timeline
3 December 2015
Primary endpoint
11 January 2019
11 January 2019
22 March 2019
Quick facts
| Lead sponsor | Effector Therapeutics |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 66 |
| Start date | 3 December 2015 |
| Primary completion | 11 January 2019 |
| Estimated completion | 22 March 2019 |
| Sites | 4 locations across United States |
Drugs / interventions tested
- eFT508 — full drug profile →
Conditions studied
- Cancer — all drugs for Cancer →
Sponsor
Effector Therapeutics — full company profile →
Who can join
18 and older, any sex, with Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of daily oral administration of eFT508.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Translation control of the immune checkpoint in cancer and its therapeutic targeting.
Xu Y, Poggio M, Jin HY, Shi Z, et al · · 2019 · cited 227× · PMID 30643286 · DOI 10.1038/s41591-018-0321-2 -
The regulation of protein translation and its implications for cancer.
Song P, Yang F, Jin H, Wang X. · · 2021 · cited 106× · PMID 33597534 · DOI 10.1038/s41392-020-00444-9 -
The eukaryotic translation initiation factor eIF4E wears a "cap" for many occasions.
Borden KL. · · 2016 · cited 42× · PMID 28090419 · DOI 10.1080/21690731.2016.1220899 -
Deeping in the Role of the MAP-Kinases Interacting Kinases (MNKs) in Cancer.
Pinto-Díez C, Ferreras-Martín R, Carrión-Marchante R, González VM, et al · · 2020 · cited 41× · PMID 32340135 · DOI 10.3390/ijms21082967 -
Cancer Cell Phenotype Plasticity as a Driver of Immune Escape in Melanoma.
Benboubker V, Boivin F, Dalle S, Caramel J. · · 2022 · cited 33× · PMID 35432344 · DOI 10.3389/fimmu.2022.873116 -
Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials.
Berger MD, Stintzing S, Heinemann V, Yang D, et al · · 2017 · cited 33× · PMID 29045529 · DOI 10.1093/annonc/mdx412 -
The MNK1/2-eIF4E Axis as a Potential Therapeutic Target in Melanoma.
Prabhu SA, Moussa O, Miller WH, Del Rincón SV. · · 2020 · cited 28× · PMID 32517051 · DOI 10.3390/ijms21114055 -
Genetic and Histopathological Heterogeneity of Neuroblastoma and Precision Therapeutic Approaches for Extremely Unfavorable Histology Subgroups.
Shimada H, Ikegaki N. · · 2022 · cited 23× · PMID 35053227 · DOI 10.3390/biom12010079
Verify or expand the search:
- PubMed search for NCT02605083
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of eFT508
Trials testing the same drug.
- NCT03690141 — An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer · Phase 2 · terminated
- NCT03318562 — A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC · Phase 2 · terminated
- NCT03258398 — A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer · Phase 2 · completed
Other recruiting trials for Cancer
Currently open trials in the same condition.
- NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors · NA · recruiting
- NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy · NA · recruiting
- NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. · NA · recruiting
- NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
- NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety · NA · recruiting
Other Effector Therapeutics trials
Trials by the same sponsor.
- NCT04632381 — Intravenous Zotatifin in Adults With Mild or Moderate COVID-19 · Phase 1 · completed
- NCT04622007 — Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART) · Phase 2 · active not recruiting
- NCT04092673 — Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies · Phase 1, PHASE2 · recruiting
- NCT03690141 — An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer · Phase 2 · terminated
- NCT03616834 — Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT02605083 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Effector Therapeutics
- Last refreshed: 2 November 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02605083.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing